The 2D-BioPAD project has wrapped up its first phase after 18 months of work, showing strong progress across multiple areas.
Biomarkers & Biosensing
Novaptech has developed the first aptamers that target Alzheimer’s-related biomarkers. These aptamers are now available for use by partners building biosensors. CeADAR has advanced its computer models to score how well aptamers bind to their targets, and AUTH has created special magnetic nanoparticles to help clean samples and improve sensor control. A method to connect these particles to aptamers has also been successfully tested.
Graphene-Based Platforms
UP-CATRIN created seven new types of graphene materials. ICN2 built a first version of an electrochemical biosensor, using laser techniques to improve how the graphene works on testing strips. GRAPHEAL developed a working graphene field-effect transistor (GFET) biosensor that can detect two biomarkers at once and started work on easier blood sample preparation.
Clinical Studies
Preparations for real-world testing are moving ahead. The pilot study plan has been approved by ethical committees in Finland, Greece, and Germany. The team is now working on updated protocols and ensuring all legal and ethical standards are met.
Partnerships & Outreach
2D-BioPAD has deepened ties with the Graphene Flagship and co-hosted Graphene Week 2024 in Prague. There, they joined forces with the MUNASET project and other related initiatives to promote the use of 2D materials in healthcare. The team also co-authored a joint article and formed new links with other European projects like GRAPHERGIA and SAFARI.
Events & Engagement
Partners have attended 33 major scientific events, sharing progress at conferences across Europe and beyond. Highlights include presentations at the Alzheimer Europe Conference, NanoBio&Med, and workshops in Spain, China, and the UK. The team has also hosted webinars, promoted the project on national media, and reached out to healthcare professionals and patient communities.
What’s Next
Work will now focus on further aptamer testing, improving biosensors, and getting ready for the next stages of clinical trials. Partners will keep pushing forward with development, while planning events and activities for continued outreach—especially at Graphene Week 2025.
